DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Eckstein M, Erben P, Kriegmair MC. et al.
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
European journal of cancer 2019;
106: 234-243
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.